Blood lipid parameters, fasted glucose, and hemoglobin A1c (HbA1c) were assessed at visit 1 and visit 6. Once you did so, you can choose a preset to change and adjust the quality of your PDF file. You can choose between "basic" and "strong" compression, and using a preset. The study evaluated the effectiveness and tolerability of Redusure (IQP-AK-102), a patent-pending fibre complex and key ingredient in bmiSMART's I-CONTROL appetite reducer, for promoting weight loss in overweight and obese individuals. Results found that subjects who received Redusure saw significantly higher weight reduction than those who received the placebo. XLS Medical Specialist Apetite Reducer helps the treatment and prevention of excess weight and general weight management.• Fills 30-43% of the stomach and promotes a pleasant feeling of fullness

As demonstrated by Zaluvida Group’s research and evidenced in InQpharm’s three bmiSMART products, efficacious, safe and easy to apply approaches to weight management do exist. They also allow adaption to individual dietary habits (such as preference for fatty foods or carbohydrate-rich diets) and can help to overcome initial hunger sensations while individuals are transitioning to a healthier diet. IQP-AE-103 demonstrated a very good tolerability profile in our study as expected since okra is typically consumed as food and inulin is widely consumed as fibre/prebiotic supplements. Additionally, okra has shown no toxicity in animals at doses up to 4000 mg/kg [ 50]. A safety review on inulin by Carabin and Flamm [ 51] has found no treatment-related toxic effects nor carcinogenicity or genotoxicity. In our study, the overall tolerability towards the IQP-AE-103 in high and low doses was comparable to that in the placebo, according to the rating by the subjects and the investigator. Observed adverse events were unrelated with the IQP-AE-103 consumption. Moreover, there were no significant differences in stool frequency. Therefore, in contrast to many available anti-obesity products that cause unpleasant and sometimes serious side effects, IQP-AE-103 could be considered as a safe, well-tolerated, and effective weight management agent. The Pharmacist reserves the right to not supply contrary to our professional and ethical obligations. Another finding of this study is that besides weight loss, IQP-AE-103 showed beneficial effects on lipid metabolism. A significantly higher proportion of subjects in the high-dose IQP-AE-103 group experienced a reduction in triglyceride levels at the end of the study compared with placebo. In subjects with higher baseline total cholesterol levels (>6.2 mmol/L), high dose of IQP-AE-103 was shown to significantly reduce total cholesterol and LDL-cholesterol (pre-post change). Therefore, current outcome suggests that long-term treatment with IQP-AE-103 could be beneficial for subjects with elevated blood lipid levels in reducing the risk of cardiovascular disease.Furthermore, no change in physical activity was noted by analyzing data from IPAQ-SF. Mean stool frequency did not change significantly in any of the study arms throughout the study. This research confirms Redusure's role in appetite reduction by promoting pleasant feelings of fullness when taken before meals,' stated Holly Tully, VP of Marketing, InQpharm NA. 'The study also reveals just how effective these appetite-reducing properties are in helping individuals lose weight at a consistent, healthy rate.' There are many factors contributing to overweight or obesity such as physical inactivity, poor diet, high calorie intake, genetics, or the way the body uses energy. Hence, reducing body weight and calorie intake, introducing balanced diet, and increasing physical activity are critical to achieve weight loss. Pharmaceutical drug therapies are indicated when lifestyle intervention alone is unsuccessful. However, the vast majority of the currently available therapies are associated with unpleasant or even serious adverse effects. Many anti-obesity drugs that have been approved by health authorities have eventually been withdrawn from the market due to serious adverse events, for example, sibutramine or rimonabant, leaving limited options, for example, orlistat. But orlistat has also a long list of side effects, such as fecal incontinence, oily spotting, diarrhea, or even more severe side effects such as serious liver injury [ 14– 16]. Since weight loss is a long-term treatment, anti-obesity medications should have good tolerability and be free of side effects. For this reason, new strategies have to be developed to combat this complex health condition. Multiple benefits: Specially developed for people who want to control appetite, reduce hunger pangs and regulate food portion sizes Don't take this product if you are allergic to sulphur-containing products (such as sulfites) or any of the ingredients listed. If you experience any allergic symptoms, such as skin rashes or difficulty in breathing or any other side effects, please consult your doctor immediately.

bmiSMART is the first weight management brand to introduce oral weight management treatments from InQpharm, a Zaluvida Group, which are based on continuous biotech innovations and research.

B. Grube, et al., “A Natural Fiber Complex Reduces Body Weight in the Overweight and Obese: A Double-Blind, Randomized, Placebo-Controlled Study,” Obesity 21, 58–64 (2013). In the next step, the weight loss and weight maintenance efficacy of IQP-AE-103 should be evaluated in longer clinical trials. Also, it would be worthwhile to further investigate any positive effect on cardiovascular risk factors associated with obesity, particularly in subjects with elevated blood lipids. For further elucidation of mode of action, an assessment of fecal fat excretion, or postprandial blood lipid changes and potentially gut microbiome study could be considered. 5. Conclusion and Implication In addition, a combination of dehydrated okra pod powder and inulin, the active ingredients in IQP-AE-103, has been shown to be a strong fat-binding agent in an in vitro setting simulating in vivo conditions (data not shown); it also exerts high swelling capacity and significantly enhances solution viscosity. Thus, IQP-AE-103 appears to be a promising natural agent that may help to control calorie intake, decrease absorption of dietary fat, and consequently lead to body weight reduction.

For you, we are running many services free of cost. Those services are expensive to run, requiring multiple servers to process and encode the files. File size reduction is available for PDF documents only. If you provide a file in another format, we convert it to PDF automatically and then compress it. That is why I chose to have Trademark Elite to register the trademark for my award-winning law blog. Ingredients Composition: Redusure®, a proprietary blend of high-swelling capacity dietary fibres, potassium bicarbonate, silicon dioxide, magnesium stearate, microcrystalline cellulose. Do not take Hunger Buddy during pregnancy or whilst breastfeeding, or if your BMI (Body Mass Index) is below 18.5. It is recommended that you calculate your BMI before and during use.XLS Medical Appetite Reducer appetite suppressant and hunger control for a more efficient weight loss Hunger Buddy is clinically proven to promote significant weight loss through a reduced food intake. It is particularly suitable for those who constantly have a big appetite and cannot control portion size. Hunger Buddy is a certified medical device product for the treatment and Direct comparisons of IQP-AE-103 with other weight loss agents that affect dietary fat absorption such as chitosan, Litramine®, or orlistat are difficult for methodological reasons. Ho et al. reported that there were no significant changes from baseline in body weight after 12 weeks of treatment with chitosan [ 39]. A treatment with Litramine® (a proprietary fibre complex) led to 3.8 kg weight loss after 12 weeks of intake [ 17]. As for orlistat (gastric and pancreatic lipase inhibitor), a study by Anderson et al. reported a 3.05 kg weight loss in overweight subjects after 16 weeks of treatment at 180 mg per day [ 40], whereas at higher dose of 360 mg per day, it caused a body weight reduction of 8.3 kg after 12-week period in obese women [ 41].